Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

30.03 +1.35 (+4.71%)
Streaming Delayed Price Updated: 9:36 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,803
Open 29.23
Bid (Size) 29.47 (100)
Ask (Size) 30.71 (200)
Prev. Close 28.68
Today's Range 28.69 - 30.03
52wk Range 6.430 - 42.27
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+63.3%
+63.3%
1 Month
+19.6%
+19.6%
3 Month
+14.2%
+14.2%
6 Month
+172.3%
+172.3%
1 Year
+57.5%
+57.5%

More News

Read More
News headline image
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened ↗
Via Stocktwits
News headline image
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗
Via Chartmill
Topics Earnings
News headline image
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Rapport Announces Pricing of Public Offering of Common Stock
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Rapport Announces Proposed Public Offering of Common Stock
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Gold Moves Higher; Robinhood Shares Jump ↗
Via Benzinga
News headline image
Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results ↗
Via Benzinga
News headline image
Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures ↗
Via Investor's Business Daily
News headline image
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is Rapport Therapeutics, Inc. - Common Stock publicly traded?
Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?
Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?
The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market
What is the current price of Rapport Therapeutics, Inc. - Common Stock?
The current price of Rapport Therapeutics, Inc. - Common Stock is 30.03
When was Rapport Therapeutics, Inc. - Common Stock last traded?
The last trade of Rapport Therapeutics, Inc. - Common Stock was at 12/18/25 09:36 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.